Akèy › Kansè ovè › Massachusetts › Boston
Etid klinik pou Kansè ovè nan Boston, MA
61 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
Ap rekrite
- Dana-Farber Cancer Institute, Boston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Ap rekriteFaz 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- Dana Farber Cancer Institute, Boston
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Ap rekriteFaz 1
- Research Site, Boston
- Research Site, Boston
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ap rekriteFaz 2
- Site 0221 - Tufts Medical Center - PPDS, Boston
- Site 0104 - Dana Farber Cancer Institute, Boston
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
Ap rekrite
- Dana Farber Cancer Institute, Boston
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber / Harvard Cancer Center, Boston
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute Brookline Avenue, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer
Ap rekriteFaz 2
- Tufts Medical Center, Boston
A Study of Isoquercetin in People With Ovarian Cancer
Ap rekriteFaz 2
- Beth Israel Deaconess Medical Center (Data Collection Only), Boston
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ap rekriteFaz 2
- Massachusetts General Hospital, Boston
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Ap rekriteFaz 1/2
- Tufts, Boston
- Dana-Farber Cancer Institute, Boston
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Ap rekriteFaz 3
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ap rekriteFaz 2
- Massachusetts General Hospital, Boston
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Boston
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Ap rekriteFaz 1
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Dana Farber Cancer Institute, Boston
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
Ap rekriteFaz 1
- Dana-Farber Cancer Institute, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Ap rekriteFaz 1
- Dana Farber Cancer Institute, Boston
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Ap rekriteFaz 1/2
- Research Site, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Ap rekriteFaz 1
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
A Study of PHST001 in Advanced Solid Tumors
Ap rekriteFaz 1
- Dana Farber Cancer Institute, Boston
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Boston
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ap rekrite
- Beth Israel Deaconess Medical Center, Boston
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Ap rekriteFaz 2
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine
Ap rekriteFaz 1
- Beth Israel Deaconess Medical Center, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- ak 2 plis
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Ap rekriteFaz 3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Ap rekriteFaz 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Ap rekriteFaz 2
- GSK Investigational Site, Boston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
Ap rekrite
- Dana-Farber Cancer Institute, Boston
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Ap rekriteFaz 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Ap rekriteFaz 1
- Dana Farber Cancer Institute, Boston
Video Education With Result Dependent dIsclosure
Ap rekrite
- Dana Farber Cancer Institute, Boston
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Ap rekriteFaz 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Ap rekrite
- Massachusetts General Hospital-Cancer Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Ap rekriteFaz 1
- Site 0104, Boston
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Ap rekrite
- Dana Farber Cancer Institute, Boston
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Ap rekriteFaz 1/2
- Dana-Farber Cancer Institute, Boston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
Ap rekrite
- Dana Farber Cancer Institute, Boston
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Ap rekriteFaz 1
- Dana Farber Cancer Institute, Boston
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Ap rekriteFaz 2
- Massachusetts General Hospital, Boston
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Ap rekriteFaz 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
Ap rekriteEtid obsèvasyon
- Massachusetts General Hospital, Boston
Comprehensive Outcomes for After Cancer Health
Ap rekriteVolontè an sante akeyi
- Dana Farber Cancer Institute, Boston
Etid Kansè ovè nan lòt vil
- Houston, TX89 etid
- New York City, NY69 etid
- Los Angeles, CA50 etid
- Nashville, TN49 etid
- Arlington, VA46 etid
- Philadelphia, PA44 etid
- Columbus, OH39 etid
- St. Louis, MO38 etid
- Chicago, IL36 etid
- San Antonio, TX31 etid
- Cleveland, OH30 etid
- Pittsburgh, PA30 etid
Lòt etid nan Boston
- Kansè nan tete111 etid
- Kansè Poumon ki pa ti selil90 etid
- Kansè (tout kalite)86 etid
- Kansè kolorektal63 etid
- Kansè Metastatik63 etid
- Kansè poumon62 etid
- Kansè pwostat59 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Ensifizyans kadyak44 etid
- Leksemi mieloïd egi44 etid
- Kansè pankreyas43 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.